JPRN-UMIN000004580已完成2 期
Study of Cetuximab + Irinotecan + S-1 as first line therapy in metastatic colorectal cancer with KRAS wild type - CIRIS study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Sever myeloablation 2. Severe infectious disease 3. Sensory alteration or paresthesia interfering with function 4. A mental disorder, nucleus neuropathy, cerebrovascular neuropathy failure 5. Comorbidity or history of heart failure 6. Interstitial lung disease or pulmonary fibrosis 7. Prior radiotherapy for primary and metastases tumors 8. History of severe allergy 9. Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test 10. Sever comorbidity (renal failure, liver failure, hypertension, high calcium, etc) 11. Symptomatic brain metastases 12. Patient have metachronous multiple malignancy 13. Any other cases who are regarded as inadequate for study enrollmet by investigators
研究者
相似试验
已完成
1 期
Cetuximab plus S-1 and irinotecan (IRIS) as first-line treatment in RAS wild type metastatic colorectal cancer, a phase I/II trial (KSCC1401)Colorectal cancerJPRN-UMIN000015835Kyushu Study group of Clinical Cancer(KSCC)57
已完成
1 期
Phase I study of TS-1+irinotecan+cetuximab as the first-line therapy in patients with KRAS wild-type metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000010639Japan Clinical Cancer Research Organization16
招募中
1 期
Phase I/II study of Cetuximab combined with S-1 and irrinotecan (CeIRIS) in KRAS wild type metastatic colorectal cancer patients refractory to treatment with oxaliplatin and fluoropyrimidine.Colorectal cancer: KRAS wild typeJPRN-UMIN000003288Kyushu Medical Oncology Group40
招募中
不适用
Phase I trial of Cetuximab combined with S-1 and irrinotecan in advanced colorectal cancercolorectal cancerJPRN-UMIN000003703Toho University school of Medicine10
已完成
2 期
Phase II study of cetuximab plus irinotecan for unresectable colorectal cancernresectable advaned or recurrent colorectal cancerJPRN-UMIN000001838Aichi Cancer Center Hospital30